

Supplementary Table 8. Absolute risk differences of therapeutic targets on histological outcomes derived from network meta-analysis odds ratios

Note: ACC, acetyl-coenzyme A carboxylase; FGF, fibroblast growth factor; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; GCG, glucagon; GIP, glucose-dependent insulinotropic polypeptide; PPAR, peroxisome proliferator-activated receptor; THR, thyroid hormone receptor; RA, receptor agonist, ACR, absolute risk difference, CI: confidence interval.

Supplementary Table 8.1 Absolute risk differences of therapeutic targets on fibrosis improvement derived from network meta-analysis odds ratios

Targets	Odds ratio (95%CI)	ACR	95%CI
FGF21 analogue	3.52 (1.81, 6.85)	24.90%	10.0%, 41.4%
FGF19 analogue	2.19 (0.97, 4.94)	14.00%	-0.4%, 33.3%
d-(R)-Pioglitazone	4.75 (1.21, 18.58)	32.30%	3.0%, 62.2%
PPAR agonist	2.94 (1.66, 5.24)	20.60%	8.4%, 34.8%
GLP-1 RA	2.02 (1.48, 2.74)	12.30%	6.3%, 19.0%
THR- β agonist	2.04 (1.45, 2.87)	12.50%	5.9%, 20.0%
FXR agonist	2.70 (1.70, 4.29)	18.60%	8.8%, 29.8%
GLP-1/GCG dual RA	3.40 (1.53, 7.56)	24.10%	6.9%, 43.8%
GLP-1/GIP dual RA	3.01 (1.29, 7.02)	21.10%	3.9%, 42.0%

Supplementary Table 8.2 Absolute risk differences of therapeutic targets on steatohepatitis improvement derived from network meta-analysis odds ratios

Targets	Odds ratio (95%CI)	ARD	95%CI
FGF21 analogue	4.06 (1.55, 10.65)	27.30%	6.6%, 50.7%
FGF19 analogue	3.84 (1.03, 14.31)	25.90%	0.4%, 56.9%
d-(R)-Pioglitazone	1.41 (0.29, 6.71)	5.10%	-10.5%, 39.7%
GLP-1 RA	4.57 (2.18, 9.55)	30.20%	13.1%, 48.2%
THR- β agonist	3.56 (1.75, 7.24)	24.10%	9.0%, 41.6%
PPAR agonist	3.11 (1.56, 6.22)	20.90%	6.7%, 37.9%
FXR agonist	2.48 (1.10, 5.60)	15.80%	1.3%, 35.3%
GLP-1/GCG dual RA	10.67 (3.07, 37.04)	50.70%	20.6%, 71.7%
GLP-1/GIP dual RA	14.33 (3.39, 60.57)	57.00%	22.9%, 76.2%